TEVA Jan 2026 25.000 call
| Previous close | 0.9600 |
| Open | 0.9100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 25.00 |
| Expiry date | 2026-01-16 |
| Day's range | 0.9000 - 1.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Investor's Business DailyTeva Pharma's Turnaround Story: How A Key Win Helped It Clinch A Five-Year High
Teva stock surged Wednesday after the company beat first-quarter views and unveiled promising results from its schizophrenia drug study.
Barrons.comTeva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings
Shares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company announced positive results in a trial of a schizophrenia medicine. Its quarterly results, also disclosed early Wednesday, were mixed. Revenue was $3.8 billion for the quarter, slightly better than the FactSet consensus estimate of $3.7 billion, while non-GAAP diluted earnings were 48 cents a share.
ZacksTeva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
